EKR Therapeutics, Inc. Broadens Its Ready-to-Use Cardene(R) I.V. Product Offerings With FDA Approval of Double Concentration Premixed I.V. Bags

BEDMINSTER, N.J.--(BUSINESS WIRE)--EKR Therapeutics, Inc., a specialty pharmaceutical company focused on providing novel products for the acute-care hospital setting, today announced that it received approval from the U.S. Food and Drug Administration (FDA) for double (2X) concentration Cardene® I.V. (nicardipine hydrochloride) premixed injection.